Recent Insider Transactions • Jan 02
Insider recently sold US$81k worth of stock On the 30th of December, Braden Leonard sold around 20k shares on-market at roughly US$4.04 per share. This transaction amounted to 8.0% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth US$203k. Insiders have been net sellers, collectively disposing of US$51k more than they bought in the last 12 months. Recent Insider Transactions • Dec 28
Insider recently sold US$203k worth of stock On the 23rd of December, Braden Leonard sold around 50k shares on-market at roughly US$4.06 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought US$111k more than they sold in the last 12 months. Announcement • Nov 12
Cardurion Pharmaceuticals, LLC acquired Tovinontrine (IMR-687) and All of the Assets Related to PDE9 Program from IMARA Inc. (NasdaqGS:IMRA) for approximately $95. Cardurion Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Tovinontrine (IMR-687) and All of the Assets Related to PDE9 Program from IMARA Inc. (NasdaqGS:IMRA) for approximately $95 on September 6, 2022. The aggregate purchase price consists of an upfront cash payment of $34,750,000 upon closing of the transaction and a $10,000,000 potential future payment that may become payable if Cardurion achieves a proof of concept milestone or other specified clinical milestones and a $50,000,000 potential future payment that may become payable if Cardurion achieves specified regulatory and/or commercial milestone events, in each case as described in the Asset Purchase Agreement and subject to the terms of the Asset Purchase Agreement. Completion of the Asset Sale is subject to approval by the Company’s stockholders and the satisfaction or waiver of other customary conditions. The Board of Directors of the Company (the “Board”) has unanimously approved the proposed transactions set forth in the Asset Purchase Agreement. The Board had engaged SVB Securities LLC (“SVB Securities”) as a financial advisor to assist the Board in reviewing a range of strategic alternatives for the Company, including the asset sale transaction. The Asset Purchase Agreement contains certain termination rights of each of the Company and Cardurion. In certain circumstances, the Company would be obligated to pay a termination fee of $1,500,000 to Cardurion.
Cardurion Pharmaceuticals, LLC completed the acquisition Tovinontrine (IMR-687) and All of the Assets Related to PDE9 Program from IMARA Inc. (NasdaqGS:IMRA) on November 10, 2022. 
